Clinical Focus ›› 2021, Vol. 36 ›› Issue (2): 168-173.doi: 10.3969/j.issn.1004-583X.2021.02.015
Previous Articles Next Articles
-
Received:2020-11-11Online:2021-02-20Published:2021-02-05
CLC Number:
Cite this article
share this article
Add to citation manager EndNote|Ris|BibTeX
URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2021.02.015
| [1] |
Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management[J]. Lancet Neurol, 2018,17(3):251-267.
doi: S1474-4422(18)30024-3 pmid: 29395989 |
| [2] | Iftikhar M, Frey J, Shohan MJ, et al. Current and emerging therapies for Duchenne muscular dystrophy and spinal muscular atrophy[J]. Pharmacol Ther, 2020: 107719. |
| [3] |
Shieh PB. Emerging Strategies in the Treatment of Duchenne Muscular Dystrophy[J]. Neurotherapeutics, 2018,15(4):840-848.
doi: 10.1007/s13311-018-00687-z URL |
| [4] |
Verhaart IEC, Aartsma-Rus A. Therapeutic developments for Duchenne muscular dystrophy[J]. Nat Rev Neurol, 2019,15(7):373-386.
doi: 10.1038/s41582-019-0203-3 pmid: 31147635 |
| [5] | Sun C, Shen L, Zhang Z, et al. Therapeutic strategies for Duchenne muscular dystrophy: An update[J]. Genes (Basel), 2020,11(8) 837. |
| [6] | Malik V, Rodino-Klapac LR, Viollet L, et al. Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy[J]. Ann Neurol, 2010,67(6):771-780. |
| [7] |
Finkel RS, Flanigan KM, Wong B, et al. Phase 2a study of ataluren-mediated dystrophin production in patients with nonsense mutation Duchenne muscular dystrophy[J]. PLoS One, 2013,8(12):e81302.
doi: 10.1371/journal.pone.0081302 URL |
| [8] |
Bushby K, Finkel R, Wong B, et al. Ataluren treatment of patients with nonsense mutation dystrophinopathy[J]. Muscle Nerve, 2014,50(4):477-487.
doi: 10.1002/mus.v50.4 URL |
| [9] |
McDonald CM, Campbell C, Torricelli RE, et al. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2017,390(10101):1489-1498.
doi: S0140-6736(17)31611-2 pmid: 28728956 |
| [10] |
Haas M, Vlcek V, Balabanov P, et al. European Medicines Agency review of ataluren for the treatment of ambulant patients aged 5 years and older with Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene[J]. Neuromuscul Disord, 2015,25(1):5-13.
doi: 10.1016/j.nmd.2014.11.011 URL |
| [11] |
Echigoya Y, Lim KRQ, Nakamura A, et al. Multiple exon skipping in the duchenne muscular dystrophy hot spots: prospects and challenges[J]. J Pers Med, 2018,8(4):41.
doi: 10.3390/jpm8040041 URL |
| [12] |
Lim KRQ, Echigoya Y, Nagata T, et al. Efficacy of multi-exon skipping treatment in Duchenne muscular dystrophy dog model neonates[J]. Mol Ther, 2019,27(1):76-86.
doi: 10.1016/j.ymthe.2018.10.011 URL |
| [13] |
Goemans N, Mercuri E, Belousova E, et al. A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy[J]. Neuromuscul Disord, 2018,28(1):4-15.
doi: 10.1016/j.nmd.2017.10.004 URL |
| [14] |
Lim KR, Maruyama R, Yokota T. Eteplirsen in the treatment of Duchenne muscular dystrophy[J]. Drug Des Devel Ther, 2017,11:533-545.
doi: 10.2147/DDDT URL |
| [15] |
Heo YA. Golodirsen: First approval[J]. Drugs, 2020,80(3):329-333.
doi: 10.1007/s40265-020-01267-2 URL |
| [16] |
Babbs A, Chatzopoulou M, Edwards B, et al. From diagnosis to therapy in Duchenne muscular dystrophy[J]. Biochem Soc Trans, 2020,48(3):813-821.
doi: 10.1042/BST20190282 URL |
| [17] | 张成, 李欢. Duchenne型肌营养不良症治疗研究进展及应用前景[J]. 中国现代神经疾病杂志, 2018,18(7):480-493. |
| [18] |
Juliano RL. The delivery of therapeutic oligonucleotides[J]. Nucleic Acids Res, 2016,44(14):6518-6548.
doi: 10.1093/nar/gkw236 URL |
| [19] |
Moulton HM, Moulton JD. Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy[J]. Biochim Biophys Acta, 2010,1798(12):2296-2303.
doi: 10.1016/j.bbamem.2010.02.012 pmid: 20170628 |
| [20] | 张淑, 吴士文. 杜氏型肌营养不良症治疗进展[J]. 实用药物与临床, 2019,22(9):897-903. |
| [21] | 张成, 林金福, 廖子钰. Duchenne型肌营养不良症基因治疗进展与思考[J]. 中国现代神经疾病杂志, 2019,19(5):312-319. |
| [22] |
Le Guiner C, Servais L, Montus M, et al. Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy[J]. Nat Commun, 2017,8:16105.
doi: 10.1038/ncomms16105 URL |
| [23] |
Okada T, Takeda S. Current challenges and future directions in recombinant AAV-mediated gene therapy of Duchenne muscular dystrophy[J]. Pharmaceuticals (Basel), 2013,6(7):813-836.
doi: 10.3390/ph6070813 URL |
| [24] |
Ousterout DG, Kabadi AM, Thakore PI, et al. Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy[J]. Nat Commun, 2015,6:6244.
doi: 10.1038/ncomms7244 pmid: 25692716 |
| [25] |
Young CS, Hicks MR, Ermolova NV, et al. A single CRISPR-Cas9 deletion strategy that targets the majority of DMD patients restores dystrophin function in hiPSC-derived muscle cells[J]. Cell Stem Cell, 2016,18(4):533-540.
doi: 10.1016/j.stem.2016.01.021 URL |
| [26] |
Béroud C, Tuffery-Giraud S, Matsuo M, et al. Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy[J]. Hum Mutat, 2007,28(2):196-202.
doi: 10.1002/humu.v28:2 URL |
| [27] | 李统宇, 梁平. 杜氏肌营养不良疾病模型及基因治疗研究进展[J]. 浙江大学学报(医学版), 2016,45(6):648-654. |
| [28] |
Matthias N, Hunt SD, Wu J, et al. Skeletal muscle perfusion and stem cell delivery in muscle disorders using intra-femoral artery canulation in mice[J]. Exp Cell Res, 2015,339(1):103-111.
doi: 10.1016/j.yexcr.2015.08.018 URL |
| [29] |
Siemionow M, Cwykiel J, Heydemann A, et al. Dystrophin expressing chimeric (DEC) human cells provide a potential therapy for Duchenne muscular dystrophy[J]. Stem Cell Rev Rep, 2018,14(3):370-384.
doi: 10.1007/s12015-018-9807-z pmid: 29546607 |
| [30] | Matthews E, Brassington R, Kuntzer T, et al. Corticosteroids for the treatment of Duchenne muscular dystrophy[J]. Cochrane Database Syst Rev, 2016, (5):CD003725. |
| [31] |
Conklin LS, Damsker JM, Hoffman EP, et al. Phase Ⅱa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug[J]. Pharmacol Res, 2018,136:140-150.
doi: 10.1016/j.phrs.2018.09.007 URL |
| [32] |
Hoffman EP, Schwartz BD, Mengle-Gaw LJ, et al. Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function[J]. Neurology, 2019,93(13):e1312-1312e1323.
doi: 10.1212/WNL.0000000000008168 pmid: WOS:000512605300009 |
| [33] |
Heier CR, Yu Q, Fiorillo AA, et al. Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy[J]. Life Sci Alliance, 2019,2(1):e201800186.
doi: 10.26508/lsa.201800186 URL |
| [34] |
Kleopa KA, Drousiotou A, Mavrikiou E, et al. Naturally occurring utrophin correlates with disease severity in Duchenne muscular dystrophy[J]. Hum Mol Genet, 2006,15(10):1623-1628.
doi: 10.1093/hmg/ddl083 URL |
| [35] |
Chatzopoulou M, Claridge TDW, Davies KE, et al. Isolation, structural Identification, synjournal, and pharmacological profiling of 1, 2-trans-dihydro-1, 2-diol metabolites of the utrophin modulator ezutromid[J]. J Med Chem, 2020,63(5):2547-2556.
doi: 10.1021/acs.jmedchem.9b01547 URL |
| [36] |
Bettica P, Petrini S, D'Oria V, et al. Histological effects of givinostat in boys with Duchenne muscular dystrophy[J]. Neuromuscul Disord, 2016,26(10):643-649.
doi: 10.1016/j.nmd.2016.07.002 URL |
| [37] |
Whitehead NP, Kim MJ, Bible KL, et al. A new therapeutic effect of simvastatin revealed by functional improvement in muscular dystrophy[J]. Proc Natl Acad Sci U S A, 2015,112(41):12864-12869.
doi: 10.1073/pnas.1509536112 URL |
| [38] |
Whitehead NP. Enhanced autophagy as a potential mechanism for the improved physiological function by simvastatin in muscular dystrophy[J]. Autophagy, 2016,12(4):705-706.
doi: 10.1080/15548627.2016.1144005 pmid: 26890413 |
| [39] |
Iwere RB, Hewitt J. Myopathy in older people receiving statin therapy: a systematic review and meta-analysis[J]. Br J Clin Pharmacol, 2015,80(3):363-371.
doi: 10.1111/bcp.12687 pmid: 26032930 |
| [40] |
Parker BA, Thompson PD. Effect of statins on skeletal muscle: exercise, myopathy, and muscle outcomes[J]. Exerc Sport Sci Rev, 2012,40(4):188-194.
pmid: 23000957 |
| [41] |
Bhardwaj S, Selvarajah S, Schneider EB. Muscular effects of statins in the elderly female: a review[J]. Clin Interv Aging, 2013,8:47-59.
doi: 10.2147/CIA.S29686 pmid: 23355775 |
| [1] | . [J]. CLINICAL FOCUS, 2014, 29(2): 177-177. |
| [2] | . [J]. Clinical Focus, 2013, 28(5): 590-592. |
| [3] | ZHANG Yi-bin;YANG Xiao-feng;WANG Hong-mei;XU Yi-feng;CUI Ji-ping;WU Yan-xiang;LV Nai-wu;SHAN Hong. Curative effect analysis on transplantation of autologous bone marrow and cord blood mesenchymal stem cells in patients with Duchenne muscular dystrophy [J]. CLINICAL FOCUS, 2010, 25(13): 1130-1133. |
| [4] | . [J]. CLINICAL FOCUS, 2010, 25(4): 353-355. |
| [5] | . [J]. CLINICAL FOCUS, 2009, 24(10): 908-0. |
| [6] | . [J]. CLINICAL FOCUS, 2008, 23(19): 1389-0. |
| [7] | . [J]. CLINICAL FOCUS, 2007, 22(23): 1736-1737. |
| [8] | . [J]. CLINICAL FOCUS, 2004, 19(13): 759-759. |
| [9] | . [J]. CLINICAL FOCUS, 2002, 17(9): 514-515. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||